Board of Directors
Felix Baker is a Managing Partner of Baker Brothers Investments which he and his brother, Julian Baker, founded in 2000. Dr. Baker’s career as a fund-manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University.
Bassil Dahiyat, Ph.D. has served as a member of our board of directors since June 2018. Dr. Dahiyat is the co-founder of Xencor (NASDAQ: XNCR), a biopharmaceutical company, and has been its President and Chief Executive Officer since the Company’s incorporation in August 1997. Dr. Dahiyat is a co-inventor of Xencor’s breakthrough XmAb® antibody engineering technology. He has led Xencor in raising over $700 million in public and private financing, creating a diverse portfolio of monoclonal antibody clinical programs for the treatment of life-threatening and debilitating diseases and establishing alliances with leading biopharmaceutical companies that generated over $200 million in upfront payments. Dr. Dahiyat holds a Ph.D. in Chemistry from Caltech and B.S. and M.S.E. degrees in Biomedical Engineering from the Johns Hopkins University. He has co-authored numerous scientific papers in the fields of protein design and drug delivery, is an inventor of 33 US and numerous foreign patents and has received scientific awards from the American Chemical Society, the Controlled Release Society, the Protein Society and Caltech.
Richard Levy, M.D. has served as a member of our board of directors since June 2018. Dr. Levy served as Executive Vice President and Chief Drug Development Officer of Incyte Corporation (NASDAQ: INCY), a biopharmaceutical company, from January 2009 to April 2016 and previously served as Senior Vice President of Drug Development from August 2003 to January 2009. Prior to joining Incyte, Dr. Levy served as Vice President, Biologic Therapies, at Celgene Corporation (NASDAQ: CELG), a biopharmaceutical company, from 2002 to 2003. From 1997 to 2002, Dr. Levy served in various executive positions with DuPont Pharmaceuticals Company, first as Vice President, Regulatory Affairs and Pharmacovigilance, and thereafter as Vice President, Medical and Commercial Strategy. Dr. Levy served at Sandoz, a pharmaceutical company and predecessor of Novartis, from 1991 to 1997 in positions of increasing responsibility in clinical research and regulatory affairs. Prior to joining the pharmaceutical industry, Dr. Levy served as an Assistant Professor of Medicine at the UCLA School of Medicine. Dr. Levy is Board Certified in Internal Medicine and Gastroenterology. He received his A.B. in Biology from Brown University, his M.D. from the University of Pennsylvania School of Medicine and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA.
Victor Perlroth co-founded Kodiak Sciences in 2009 and is the company’s Chairman and Chief Executive Officer. Together with a talented core team, Dr. Perlroth has built Kodiak on a foundation of scientific excellence with a simple mission—to design and develop important new medicines for highly prevalent diseases. Under Dr. Perlroth’s leadership, Kodiak is building a pipeline of potentially life transforming ophthalmology drug candidates with the goal to build a dominant retinal franchise for the benefit of patients globally. Previously, Dr. Perlroth served as Venture Partner and then Entrepreneur in Residence at MPM Capital, a dedicated healthcare venture capital investment firm. In 2003, Dr. Perlroth co-founded Avidia Inc., a biopharmaceuticals drug discovery and development company where he served as General Manager and Vice President of Corporate Development. In this role, at various times he had broad management responsibility across both corporate and research and development activities. Dr. Perlroth was one of two principals involved in the acquisition of the company by Amgen for $450 million. Earlier, Dr. Perlroth worked at Guzik Technical Enterprises, the industry-leading provider of test equipment to the hard disk drive industry, where he was Chief Operating Officer. Dr. Perlroth earned his M.D. and M.B.A. degrees from Stanford University and an A.B. in Molecular Biology summa cum laude from Princeton University.
Robert Profusek, J.D. has served as a member of our board of directors since June 2018. Mr. Profusek is a partner at Jones Day, a global law firm of over 2,500 attorneys, where he chairs the firm’s global M&A practice. Since joining Jones Day in 1975, Mr. Profusek has become a widely-recognized expert in mergers, acquisitions, and corporate governance matters, including shareholder activism and executive compensation. Mr. Profusek also currently serves as the lead independent director of both CTS Corporation (NYSE: CTS), a designer and manufacturer of sensors, actuators and electronic components, and Valero Energy Corporation (NYSE: VLO), an international manufacturer and marketer of transportation fuels and other petrochemical products. Mr. Profusek is a frequent speaker regarding corporate takeovers and corporate governance, has authored or co-authored numerous articles, has testified before Congress and the SEC about takeover and compensation-related matters and is a frequent guest commentator on CNBC, CNN and Bloomberg TV. Mr. Profusek holds a J.D. from New York University and a B.A. from Cornell University.
Taiyin Yang, Ph.D. has served as a member of our board of directors since December 2019. Dr. Yang joined Gilead in 1993 and was appointed to her current role of Executive Vice President, Pharmaceutical Development and Manufacturing in January 2015. She is responsible for the chemistry, manufacturing and control operations of small molecules and biologics encompassing process development, production, supply chain management, analytical operations, laboratory information and quality assurance for Gilead’s investigational and commercial products. Prior to joining Gilead, Dr. Yang was Director of Analytical Chemistry at Syntex. She received her bachelor’s degree in Chemistry from National Taiwan University and her PhD in Organic Chemistry from the University of Southern California. Dr. Yang was inducted as fellow of the American Institute for Medical and Biological Engineering in 2021 and elected a member of the National Academy of Engineering in 2022. She is also a member of the Expert Scientific Advisory Committee of the Medicines for Malaria Venture.